Logo image of PHN.MI

PHARMANUTRA SPA (PHN.MI) Stock Fundamental Analysis

Europe - BIT:PHN - IT0005274094 - Common Stock

46.475 EUR
-0.82 (-1.74%)
Last: 10/23/2025, 4:17:59 PM
Fundamental Rating

7

Taking everything into account, PHN scores 7 out of 10 in our fundamental rating. PHN was compared to 13 industry peers in the Personal Care Products industry. Both the health and profitability get an excellent rating, making PHN a very profitable company, without any liquidiy or solvency issues. PHN is valued quite expensively, but it does show have an excellent growth rating. These ratings could make PHN a good candidate for growth and quality investing.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

In the past year PHN was profitable.
In the past year PHN had a positive cash flow from operations.
PHN had positive earnings in each of the past 5 years.
In the past 5 years PHN always reported a positive cash flow from operatings.
PHN.MI Yearly Net Income VS EBIT VS OCF VS FCFPHN.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

1.2 Ratios

Looking at the Return On Assets, with a value of 20.41%, PHN belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
Looking at the Return On Equity, with a value of 38.54%, PHN belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
PHN has a better Return On Invested Capital (26.24%) than 100.00% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for PHN is above the industry average of 12.37%.
The last Return On Invested Capital (26.24%) for PHN is above the 3 year average (17.21%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 20.41%
ROE 38.54%
ROIC 26.24%
ROA(3y)13.53%
ROA(5y)17.42%
ROE(3y)26.61%
ROE(5y)29.54%
ROIC(3y)17.21%
ROIC(5y)18.21%
PHN.MI Yearly ROA, ROE, ROICPHN.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

1.3 Margins

Looking at the Profit Margin, with a value of 13.48%, PHN is in the better half of the industry, outperforming 76.92% of the companies in the same industry.
In the last couple of years the Profit Margin of PHN has declined.
PHN has a Operating Margin of 21.87%. This is amongst the best in the industry. PHN outperforms 100.00% of its industry peers.
In the last couple of years the Operating Margin of PHN has remained more or less at the same level.
Looking at the Gross Margin, with a value of 97.04%, PHN belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
PHN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 21.87%
PM (TTM) 13.48%
GM 97.04%
OM growth 3Y-4.84%
OM growth 5Y1.01%
PM growth 3Y-10.74%
PM growth 5Y-1.82%
GM growth 3Y-0.75%
GM growth 5Y-0.04%
PHN.MI Yearly Profit, Operating, Gross MarginsPHN.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so PHN is creating value.
Compared to 1 year ago, PHN has about the same amount of shares outstanding.
The number of shares outstanding for PHN has been reduced compared to 5 years ago.
The debt/assets ratio for PHN has been reduced compared to a year ago.
PHN.MI Yearly Shares OutstandingPHN.MI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
PHN.MI Yearly Total Debt VS Total AssetsPHN.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

An Altman-Z score of 8.79 indicates that PHN is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 8.79, PHN belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
The Debt to FCF ratio of PHN is 2.70, which is a good value as it means it would take PHN, 2.70 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 2.70, PHN is doing good in the industry, outperforming 69.23% of the companies in the same industry.
A Debt/Equity ratio of 0.28 indicates that PHN is not too dependend on debt financing.
PHN has a better Debt to Equity ratio (0.28) than 61.54% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.28
Debt/FCF 2.7
Altman-Z 8.79
ROIC/WACC3.32
WACC7.91%
PHN.MI Yearly LT Debt VS Equity VS FCFPHN.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

PHN has a Current Ratio of 2.06. This indicates that PHN is financially healthy and has no problem in meeting its short term obligations.
PHN has a better Current ratio (2.06) than 92.31% of its industry peers.
PHN has a Quick Ratio of 1.75. This is a normal value and indicates that PHN is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.75, PHN belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.06
Quick Ratio 1.75
PHN.MI Yearly Current Assets VS Current LiabilitesPHN.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

7

3. Growth

3.1 Past

PHN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.20%, which is quite impressive.
The Earnings Per Share has been growing by 14.63% on average over the past years. This is quite good.
PHN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 15.06%.
Measured over the past years, PHN shows a quite strong growth in Revenue. The Revenue has been growing by 16.59% on average per year.
EPS 1Y (TTM)20.2%
EPS 3Y6.71%
EPS 5Y14.63%
EPS Q2Q%3.36%
Revenue 1Y (TTM)15.06%
Revenue growth 3Y19.25%
Revenue growth 5Y16.59%
Sales Q2Q%10.35%

3.2 Future

The Earnings Per Share is expected to grow by 13.52% on average over the next years. This is quite good.
Based on estimates for the next years, PHN will show a quite strong growth in Revenue. The Revenue will grow by 12.05% on average per year.
EPS Next Y8.85%
EPS Next 2Y12.93%
EPS Next 3Y13.52%
EPS Next 5YN/A
Revenue Next Year14.06%
Revenue Next 2Y14.01%
Revenue Next 3Y13.43%
Revenue Next 5Y12.05%

3.3 Evolution

The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
PHN.MI Yearly Revenue VS EstimatesPHN.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
PHN.MI Yearly EPS VS EstimatesPHN.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.5 1 1.5 2 2.5

3

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 18.97, PHN is valued on the expensive side.
Based on the Price/Earnings ratio, PHN is valued a bit cheaper than 76.92% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.57, PHN is valued a bit cheaper.
A Price/Forward Earnings ratio of 19.16 indicates a rather expensive valuation of PHN.
Compared to the rest of the industry, the Price/Forward Earnings ratio of PHN is on the same level as its industry peers.
PHN is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 23.09, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 18.97
Fwd PE 19.16
PHN.MI Price Earnings VS Forward Price EarningsPHN.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, PHN is valued a bit cheaper than the industry average as 61.54% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of PHN indicates a slightly more expensive valuation: PHN is more expensive than 76.92% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 54.92
EV/EBITDA 10.76
PHN.MI Per share dataPHN.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PHN does not grow enough to justify the current Price/Earnings ratio.
PHN has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as PHN's earnings are expected to grow with 13.52% in the coming years.
PEG (NY)2.14
PEG (5Y)1.3
EPS Next 2Y12.93%
EPS Next 3Y13.52%

6

5. Dividend

5.1 Amount

PHN has a Yearly Dividend Yield of 2.06%. Purely for dividend investing, there may be better candidates out there.
PHN's Dividend Yield is a higher than the industry average which is at 2.56.
PHN's Dividend Yield is comparable with the S&P500 average which is at 2.32.
Industry RankSector Rank
Dividend Yield 2.06%

5.2 History

On average, the dividend of PHN grows each year by 11.21%, which is quite nice.
Dividend Growth(5Y)11.21%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

PHN pays out 40.63% of its income as dividend. This is a bit on the high side, but may be sustainable.
PHN's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP40.63%
EPS Next 2Y12.93%
EPS Next 3Y13.52%
PHN.MI Yearly Income VS Free CF VS DividendPHN.MI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M
PHN.MI Dividend Payout.PHN.MI Dividend Payout, showing the Payout Ratio.PHN.MI Dividend Payout.PayoutRetained Earnings

PHARMANUTRA SPA

BIT:PHN (10/23/2025, 4:17:59 PM)

46.475

-0.82 (-1.74%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)09-08 2025-09-08
Earnings (Next)11-09 2025-11-09
Inst Owners17.08%
Inst Owner ChangeN/A
Ins Owners65.02%
Ins Owner ChangeN/A
Market Cap449.88M
Revenue(TTM)175.08M
Net Income(TTM)23.61M
Analysts83.33
Price Target80.58 (73.38%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.06%
Yearly Dividend0.85
Dividend Growth(5Y)11.21%
DP40.63%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.66%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-3.98%
EPS NY rev (3m)-6.53%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.53%
Revenue NY rev (3m)-0.29%
Valuation
Industry RankSector Rank
PE 18.97
Fwd PE 19.16
P/S 2.57
P/FCF 54.92
P/OCF 36.5
P/B 7.35
P/tB 12.05
EV/EBITDA 10.76
EPS(TTM)2.45
EY5.27%
EPS(NY)2.43
Fwd EY5.22%
FCF(TTM)0.85
FCFY1.82%
OCF(TTM)1.27
OCFY2.74%
SpS18.09
BVpS6.33
TBVpS3.86
PEG (NY)2.14
PEG (5Y)1.3
Graham Number18.68
Profitability
Industry RankSector Rank
ROA 20.41%
ROE 38.54%
ROCE 45.24%
ROIC 26.24%
ROICexc 32.19%
ROICexgc 49.25%
OM 21.87%
PM (TTM) 13.48%
GM 97.04%
FCFM 4.68%
ROA(3y)13.53%
ROA(5y)17.42%
ROE(3y)26.61%
ROE(5y)29.54%
ROIC(3y)17.21%
ROIC(5y)18.21%
ROICexc(3y)25.61%
ROICexc(5y)33.67%
ROICexgc(3y)43.23%
ROICexgc(5y)50.61%
ROCE(3y)29.76%
ROCE(5y)31.61%
ROICexgc growth 3Y-15.98%
ROICexgc growth 5Y-10.26%
ROICexc growth 3Y-20.69%
ROICexc growth 5Y-11.75%
OM growth 3Y-4.84%
OM growth 5Y1.01%
PM growth 3Y-10.74%
PM growth 5Y-1.82%
GM growth 3Y-0.75%
GM growth 5Y-0.04%
F-Score7
Asset Turnover1.51
Health
Industry RankSector Rank
Debt/Equity 0.28
Debt/FCF 2.7
Debt/EBITDA 0.4
Cap/Depr 97.13%
Cap/Sales 2.36%
Interest Coverage 250
Cash Conversion 28.97%
Profit Quality 34.7%
Current Ratio 2.06
Quick Ratio 1.75
Altman-Z 8.79
F-Score7
WACC7.91%
ROIC/WACC3.32
Cap/Depr(3y)763.09%
Cap/Depr(5y)544.05%
Cap/Sales(3y)14.97%
Cap/Sales(5y)11.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.2%
EPS 3Y6.71%
EPS 5Y14.63%
EPS Q2Q%3.36%
EPS Next Y8.85%
EPS Next 2Y12.93%
EPS Next 3Y13.52%
EPS Next 5YN/A
Revenue 1Y (TTM)15.06%
Revenue growth 3Y19.25%
Revenue growth 5Y16.59%
Sales Q2Q%10.35%
Revenue Next Year14.06%
Revenue Next 2Y14.01%
Revenue Next 3Y13.43%
Revenue Next 5Y12.05%
EBIT growth 1Y14.83%
EBIT growth 3Y13.47%
EBIT growth 5Y17.77%
EBIT Next Year22.06%
EBIT Next 3Y16.37%
EBIT Next 5Y9.96%
FCF growth 1Y144.25%
FCF growth 3Y1.75%
FCF growth 5Y17.94%
OCF growth 1Y38.33%
OCF growth 3Y0.14%
OCF growth 5Y11.34%